SCHEMBL1634405

SCHEMBL1634405

CCC(Cc1cccc(O)c1)C(=O)O

nearest known ligand 0.66

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 1/20 0.56
GRIA2 P42262 1/20 0.51
PPARG P37231 3/20 0.50
PLA2G10 O15496 1/20 0.50
PLA2G2A P14555 1/20 0.50
ANPEP P15144 1/20 0.49
ERAP2 Q6P179 1/20 0.49
ERAP1 Q9NZ08 1/20 0.49
FOLH1 Q04609 4/20 0.49
PPARA Q07869 3/20 0.48
EPHX2 P34913 1/20 0.47
CPA1 P15085 2/20 0.46
CPA3 P15088 2/20 0.46
CPB1 P15086 1/20 0.46
CPB2 Q96IY4 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5679935 1.00 CYP1A2 (0.56) CYP1A2GRIA2PPARGPLA2G10PLA2G2A
SCHEMBL10009088 0.87 FOLH1 (0.51) CYP1A2GRIA2PPARGANPEPERAP2
SCHEMBL22714101 0.83 GRIA2 (0.55) CYP1A2GRIA2ANPEPERAP2ERAP1
SCHEMBL14885274 0.83 CYP1A2 (0.56) CYP1A2PPARGPLA2G10PLA2G2AFOLH1
SCHEMBL4337145 0.83 EPHX2 (0.52) PPARGPPARAEPHX2
SCHEMBL265063 0.82 CYP1A2 (0.83) CYP1A2PPARGFOLH1PPARACPA1
SCHEMBL491524 0.82 CYP1A2 (0.83) CYP1A2PPARGFOLH1PPARACPA1
SCHEMBL265514 0.82 CYP1A2 (0.83) CYP1A2PPARGFOLH1PPARACPA1
SCHEMBL1068216 0.82 CYP1A2 (0.55) CYP1A2PPARGPLA2G10PLA2G2AFOLH1
SCHEMBL14885329 0.82 SLC1A1 (0.57) CYP1A2PPARGPLA2G10PLA2G2AFOLH1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1601251-B1 COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS WELLSTAT THERAPEUTICS CORP (US) 2014-11-12 EP disclosed
US-7932290-B2 Method for the treatment of metabolic disorders WELLSTAT BIOLOGICS CORPORATION (US) 2011-04-26 US disclosed
EP-2266946-A2 Compound For The Treatment Of Metabolic Disorders Wellstat Therapeutics Corporation (US) 2010-12-29 EP disclosed
US-20100087541-A1 COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS WELLSTAT THERAPEUTICS CORPORATION (US) 2010-04-08 US disclosed
US-7615575-B2 Compounds for the treatment of metabolic disorders WELLSTAT THERAPEUTICS CORPORATION (US) 2009-11-10 US disclosed
US-7605181-B2 Method for the treatment of metabolic disorders Wellstat Therapeutics Orporation (US) 2009-10-20 US disclosed
US-20080015254-A1 COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS WELLSTAT THERAPEUTICS CORPORATION (US) 2008-01-17 US disclosed
EP-1601251-A4 COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS WELLSTAT THERAPEUTICS CORP (US) 2007-03-28 EP disclosed
US-20060247309-A1 Compounds for the treatment of metabolic disorders PHARMA CINQ, LLC 2006-11-02 US disclosed
EP-1601251-A2 COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS Wellstat Therapeutics Corporation (US) 2005-12-07 EP disclosed
WO-2004073611-A2 COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS WELLSTAT THERAPEUTICS CORPORATION (US) 2004-09-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100087541-A1 COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS CPT1B, FABP1, CPT1A CYP1A2 2463/4885GRIA2 3796/4885PPARG 128/4885
US-20080015254-A1 COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS CPT1B, FABP1, CPT1A CYP1A2 2463/4885GRIA2 3796/4885PPARG 128/4885
US-20060247309-A1 Compounds for the treatment of metabolic disorders CPT1B, CPT1A, FABP1 CYP1A2 1678/4885GRIA2 3543/4885PPARG 287/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.